| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.658 | 0.004 | 0.658 | GABA C receptor rho-3 antagonist | 0.49 0.028 DBMET00708 0.355 0.083 DBMET00709 | ||
| 0.611 | 0.004 | 0.611 | Peroxidase inhibitor | 0.495 0.01 DBMET00708 0.525 0.008 DBMET00709 | ||
| 0.55 | 0.009 | 0.55 | Dyrk kinase inhibitor | |||
| 0.545 | 0.017 | 0.545 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.395 0.105 DBMET00708 0.272 0.253 DBMET00709 | ||
| 0.52 | 0.011 | 0.52 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | |||
| 0.504 | 0.004 | 0.504 | Protein kinase (CK1) gamma 3 inhibitor | 0.224 0.036 DBMET00709 | ||
| 0.481 | 0.004 | 0.481 | GABA C receptor agonist | 0.309 0.009 DBMET00708 0.148 0.035 DBMET00709 | ||
| 0.48 | 0.005 | 0.48 | Protein kinase (CK1) gamma 1 inhibitor | |||
| 0.496 | 0.028 | 0.496 | 5 Hydroxytryptamine release stimulant | 0.271 0.08 DBMET00708 | ||
| 0.466 | 0.009 | 0.466 | CDC-like kinase 4 inhibitor | |||
| 0.464 | 0.01 | 0.464 | Clk dual-specificity kinase inhibitor | |||
| 0.458 | 0.005 | 0.458 | Protein kinase (CK1) gamma inhibitor | 0.133 0.078 DBMET00709 | ||
| 0.458 | 0.007 | 0.458 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.172 0.1 DBMET00709 | ||
| 0.451 | 0.004 | 0.451 | Rho-associated kinase II inhibitor | |||
| 0.452 | 0.01 | 0.452 | Death-associated protein kinase 3 inhibitor | |||
| 0.472 | 0.04 | 0.5 | Histamine release inhibitor | 0.214 0.186 DBMET00708 0.5 0.029 DBMET00709 | DBMET00709 | |
| 0.46 | 0.03 | 0.46 | MAP kinase kinase 6 inhibitor | |||
| 0.44 | 0.013 | 0.44 | Calcium channel activator | 0.385 0.03 DBMET00708 0.326 0.068 DBMET00709 | ||
| 0.43 | 0.006 | 0.43 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.141 0.084 DBMET00709 | ||
| 0.428 | 0.005 | 0.428 | Rho-associated kinase inhibitor | |||
| 0.431 | 0.01 | 0.431 | CDC-like kinase 2 inhibitor | |||
| 0.44 | 0.02 | 0.59 | Superoxide dismutase inhibitor | 0.247 0.076 DBMET00708 0.59 0.007 DBMET00709 | DBMET00709 | |
| 0.41 | 0.009 | 0.41 | Protein kinase C nu inhibitor | |||
| 0.442 | 0.055 | 0.442 | 5 Hydroxytryptamine release inhibitor | 0.353 0.113 DBMET00708 | ||
| 0.389 | 0.003 | 0.389 | MAP kinase kinase 3 inhibitor | 0.258 0.024 DBMET00709 | ||
| 0.396 | 0.018 | 0.396 | Ca2+/calmodulin-dependent protein kinase inhibitor | |||
| 0.393 | 0.023 | 0.393 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.218 0.137 DBMET00708 | ||
| 0.402 | 0.037 | 0.402 | Aryl hydrocarbon receptor agonist | |||
| 0.382 | 0.018 | 0.382 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | |||
| 0.371 | 0.009 | 0.371 | Interleukin 6 antagonist | |||
| 0.401 | 0.047 | 0.401 | Aldehyde oxidase inhibitor | 0.359 0.054 DBMET00708 | ||
| 0.369 | 0.017 | 0.369 | MAP kinase kinase 2 inhibitor | 0.139 0.131 DBMET00708 | ||
| 0.373 | 0.022 | 0.373 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | |||
| 0.354 | 0.003 | 0.354 | Toll-Like receptor 3 antagonist | |||
| 0.353 | 0.005 | 0.353 | Nitric-oxide synthase stimulant | 0.234 0.045 DBMET00708 0.218 0.063 DBMET00709 | ||
| 0.356 | 0.01 | 0.356 | Ca2+/calmodulin-dependent kinase II delta inhibitor | |||
| 0.359 | 0.012 | 0.359 | Lipocortins synthesis antagonist | |||
| 0.436 | 0.091 | 0.436 | Caspase 9 stimulant | 0.299 0.195 DBMET00708 | ||
| 0.396 | 0.056 | 0.396 | Vasodilator, peripheral | 0.214 0.16 DBMET00708 | ||
| 0.347 | 0.012 | 0.347 | Protein kinase (CK1) inhibitor | |||
| 0.355 | 0.023 | 0.355 | Anesthetic general | |||
| 0.34 | 0.013 | 0.34 | LIM domain kinase 1 inhibitor | |||
| 0.332 | 0.007 | 0.332 | Protein kinase (CK1) gamma 2 inhibitor | 0.111 0.073 DBMET00709 | ||
| 0.345 | 0.024 | 0.345 | Ca2+/calmodulin-dependent kinase II beta inhibitor | |||
| 0.328 | 0.009 | 0.328 | Ribosomal protein S6 kinase inhibitor | |||
| 0.344 | 0.025 | 0.45 | RNA-directed DNA polymerase inhibitor | 0.245 0.052 DBMET00708 0.45 0.014 DBMET00709 | DBMET00709 | |
| 0.322 | 0.005 | 0.322 | GABA C receptor rho-2 antagonist | 0.194 0.032 DBMET00708 0.128 0.109 DBMET00709 | ||
| 0.319 | 0.003 | 0.333 | Acetylcholine release stimulant | 0.333 0.003 DBMET00709 | DBMET00709 | |
| 0.329 | 0.019 | 0.329 | TRKC antagonist | |||
| 0.319 | 0.01 | 0.319 | MAP kinase 9 inhibitor | |||
| 0.393 | 0.086 | 0.393 | Calcium channel L-type activator | 0.271 0.184 DBMET00708 | ||
| 0.318 | 0.012 | 0.318 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | |||
| 0.313 | 0.01 | 0.313 | Interleukin 1 antagonist | |||
| 0.344 | 0.048 | 0.344 | Interleukin 2 agonist | 0.211 0.171 DBMET00708 | ||
| 0.323 | 0.035 | 0.323 | 5 Hydroxytryptamine uptake stimulant | 0.245 0.086 DBMET00708 | ||
| 0.288 | 0.005 | 0.288 | GABA C receptor antagonist | 0.147 0.031 DBMET00708 0.196 0.014 DBMET00709 | ||
| 0.32 | 0.037 | 0.32 | DNA synthesis inhibitor | 0.214 0.102 DBMET00708 0.201 0.121 DBMET00709 | ||
| 0.316 | 0.04 | 0.316 | Interleukin agonist | |||
| 0.293 | 0.017 | 0.293 | I kappa B kinase epsilon inhibitor | |||
| 0.286 | 0.011 | 0.286 | Glutamate receptor antagonist | 0.184 0.031 DBMET00709 | ||
| 0.279 | 0.006 | 0.279 | Porphobilinogen synthase inhibitor | 0.17 0.017 DBMET00708 0.145 0.021 DBMET00709 | ||
| 0.287 | 0.014 | 0.287 | Polo-like kinase-3 inhibitor | |||
| 0.274 | 0.004 | 0.274 | GABA C receptor rho-1 antagonist | 0.132 0.031 DBMET00708 0.092 0.074 DBMET00709 | ||
| 0.278 | 0.009 | 0.278 | MAP kinase 12 inhibitor | |||
| 0.277 | 0.008 | 0.277 | MAP kinase 13 inhibitor | |||
| 0.272 | 0.007 | 0.272 | Pim-1 kinase inhibitor | |||
| 0.302 | 0.04 | 0.302 | Anticonvulsant | |||
| 0.288 | 0.028 | 0.288 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.153 0.141 DBMET00708 | ||
| 0.283 | 0.023 | 0.283 | Neurotrophic factor enhancer | |||
| 0.293 | 0.034 | 0.293 | MAP-kinase-activated kinase 5 inhibitor | |||
| 0.261 | 0.007 | 0.458 | Protein kinase C zeta inhibitor | 0.101 0.05 DBMET00708 0.458 0.003 DBMET00709 | DBMET00709 | |
| 0.266 | 0.013 | 0.266 | Cyclin-dependent kinase 8 inhibitor | |||
| 0.264 | 0.011 | 0.264 | Ferrochelatase inhibitor | 0.121 0.053 DBMET00708 | ||
| 0.271 | 0.024 | 0.271 | Tumour necrosis factor antagonist | |||
| 0.266 | 0.02 | 0.266 | Alpha-N-acetylglucosaminidase inhibitor | 0.212 0.031 DBMET00708 | ||
| 0.254 | 0.014 | 0.254 | 5 Hydroxytryptamine 3E antagonist | 0.191 0.079 DBMET00708 | ||
| 0.242 | 0.004 | 0.242 | Transforming growth factor beta 3 antagonist | 0.079 0.069 DBMET00709 | ||
| 0.266 | 0.029 | 0.266 | Focal adhesion kinase 2 inhibitor | |||
| 0.276 | 0.039 | 0.276 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | |||
| 0.281 | 0.044 | 0.282 | Tyrosine 3 hydroxylase inhibitor | 0.282 0.043 DBMET00708 | DBMET00708 | |
| 0.247 | 0.012 | 0.247 | Carbonic anhydrase XV inhibitor | 0.098 0.07 DBMET00708 0.126 0.042 DBMET00709 | ||
| 0.247 | 0.017 | 0.247 | Vascular endothelial growth factor 1 antagonist | |||
| 0.234 | 0.005 | 0.234 | Alcohol oxidase inhibitor | 0.118 0.014 DBMET00708 | ||
| 0.29 | 0.065 | 0.29 | Insulysin inhibitor | 0.243 0.103 DBMET00708 | ||
| 0.309 | 0.085 | 0.462 | Cholesterol antagonist | 0.462 0.039 DBMET00709 | DBMET00709 | |
| 0.242 | 0.02 | 0.242 | CDC-like kinase 1 inhibitor | |||
| 0.244 | 0.022 | 0.244 | Activin receptor-like kinase 2 inhibitor | |||
| 0.228 | 0.008 | 0.228 | Interleukin 8 antagonist | |||
| 0.284 | 0.064 | 0.284 | DNA damaging | |||
| 0.266 | 0.048 | 0.266 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.194 0.183 DBMET00708 | ||
| 0.249 | 0.032 | 0.249 | Growth factor agonist | |||
| 0.268 | 0.055 | 0.268 | Cyclic AMP phosphodiesterase inhibitor | |||
| 0.212 | 0.006 | 0.212 | CYP2A6 inhibitor | 0.073 0.055 DBMET00708 | ||
| 0.265 | 0.059 | 0.265 | 5 Hydroxytryptamine 1E antagonist | |||
| 0.236 | 0.03 | 0.236 | Vascular endothelial growth factor 3 antagonist | |||
| 0.214 | 0.009 | 0.214 | HIV-1 integrase (Overall Integration) inhibitor | 0.098 0.057 DBMET00708 0.113 0.044 DBMET00709 | ||
| 0.259 | 0.055 | 0.259 | Psychostimulant | |||
| 0.254 | 0.05 | 0.254 | ErbB-1 antagonist | |||
| 0.229 | 0.026 | 0.229 | NADPH oxidase inhibitor | |||
| 0.212 | 0.008 | 0.212 | MAP kinase 11 inhibitor | |||
| 0.26 | 0.058 | 0.26 | Interleukin antagonist | |||
| 0.206 | 0.004 | 0.206 | Lanosterol 14 alpha demethylase inhibitor | |||
| 0.221 | 0.02 | 0.233 | Cystathionine beta-synthase inhibitor | 0.233 0.018 DBMET00708 | DBMET00708 | |
| 0.203 | 0.004 | 0.203 | Protein kinase C epsilon inhibitor | 0.088 0.016 DBMET00708 | ||
| 0.233 | 0.035 | 0.233 | 3C-like protease (Human coronavirus) inhibitor | |||
| 0.209 | 0.012 | 0.209 | 5 Hydroxytryptamine 3A agonist | 0.113 0.062 DBMET00708 | ||
| 0.211 | 0.014 | 0.211 | Beta amyloid protein antagonist | 0.153 0.038 DBMET00709 | ||
| 0.2 | 0.005 | 0.2 | Potassium channel (Ca-activated) blocker | |||
| 0.217 | 0.024 | 0.217 | Protein kinase (CK1) delta inhibitor | |||
| 0.2 | 0.007 | 0.2 | Phenylalanine 4-hydroxylase inhibitor | 0.104 0.024 DBMET00708 0.098 0.027 DBMET00709 | ||
| 0.279 | 0.086 | 0.279 | Nootropic | |||
| 0.337 | 0.145 | 0.337 | MAP kinase 1 inhibitor | |||
| 0.204 | 0.014 | 0.204 | Adenylate kinase inhibitor | 0.117 0.046 DBMET00708 0.126 0.039 DBMET00709 | ||
| 0.217 | 0.028 | 0.217 | Glycogen synthase kinase-3 inhibitor | |||
| 0.216 | 0.027 | 0.216 | Hexokinase inhibitor | |||
| 0.193 | 0.006 | 0.193 | Histamine N-methyltransferase inhibitor | 0.108 0.039 DBMET00708 0.08 0.066 DBMET00709 | ||
| 0.286 | 0.1 | 0.728 | Angiogenesis inhibitor | 0.728 0.008 DBMET00709 | DBMET00709 | |
| 0.225 | 0.04 | 0.225 | Histone acetyltransferase inhibitor | |||
| 0.197 | 0.013 | 0.197 | Histidine decarboxylase inhibitor | 0.158 0.018 DBMET00708 | ||
| 0.191 | 0.007 | 0.191 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.077 0.022 DBMET00708 0.058 0.037 DBMET00709 | ||
| 0.192 | 0.009 | 0.192 | Electrolyte absorption antagonist | 0.087 0.081 DBMET00708 | ||
| 0.192 | 0.01 | 0.192 | Pim-3 kinase inhibitor | |||
| 0.187 | 0.005 | 0.187 | Transforming growth factor antagonist | |||
| 0.214 | 0.035 | 0.214 | Lck kinase inhibitor | |||
| 0.184 | 0.006 | 0.184 | I kappa B kinase 1 inhibitor | 0.165 0.008 DBMET00708 | ||
| 0.197 | 0.02 | 0.197 | Nav1.6 sodium channel blocker | |||
| 0.203 | 0.027 | 0.203 | MAP kinase kinase inhibitor | 0.099 0.096 DBMET00709 | ||
| 0.191 | 0.016 | 0.191 | Protein kinase C gamma inhibitor | 0.138 0.039 DBMET00708 | ||
| 0.184 | 0.012 | 0.184 | Glutamate (mGluR) antagonist | |||
| 0.248 | 0.076 | 0.248 | Tumour necrosis factor alpha release inhibitor | |||
| 0.2 | 0.028 | 0.2 | Glycogen synthase kinase-3 beta inhibitor | |||
| 0.25 | 0.078 | 0.25 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | |||
| 0.21 | 0.041 | 0.21 | Succinate dehydrogenase inhibitor | 0.187 0.06 DBMET00708 0.153 0.107 DBMET00709 | ||
| 0.193 | 0.024 | 0.193 | Cyclin-dependent kinase 5 inhibitor | |||
| 0.189 | 0.02 | 0.189 | Adenylate cyclase stimulant | 0.148 0.066 DBMET00708 0.172 0.034 DBMET00709 | ||
| 0.177 | 0.008 | 0.177 | MAP-kinase-activated kinase inhibitor | |||
| 0.194 | 0.026 | 0.194 | Protein kinase (CK2) alpha inhibitor | |||
| 0.301 | 0.134 | 0.48 | Antibacterial | 0.25 0.176 DBMET00708 0.48 0.046 DBMET00709 | DBMET00709 | |
| 0.18 | 0.012 | 0.18 | NADH dehydrogenase inhibitor | 0.117 0.03 DBMET00708 0.109 0.035 DBMET00709 | ||
| 0.228 | 0.061 | 0.228 | DNA methylase inhibitor | 0.175 0.096 DBMET00708 | ||
| 0.193 | 0.026 | 0.193 | CF transmembrane conductance regulator agonist | 0.13 0.119 DBMET00708 | ||
| 0.276 | 0.109 | 0.276 | Vasodilator, coronary | |||
| 0.184 | 0.017 | 0.184 | Activin receptor-like kinase 4 inhibitor | |||
| 0.188 | 0.022 | 0.188 | Interleukin 1b antagonist | |||
| 0.174 | 0.009 | 0.174 | MAP kinase kinase 1 inhibitor | |||
| 0.183 | 0.019 | 0.183 | Carbonic anhydrase III inhibitor | 0.132 0.037 DBMET00709 | ||
| 0.204 | 0.04 | 0.204 | Glycogen synthase kinase-3 alpha inhibitor | 0.108 0.095 DBMET00708 | ||
| 0.196 | 0.033 | 0.196 | Mannose-6-phosphate isomerase inhibitor | |||
| 0.169 | 0.006 | 0.169 | Glutamate release inhibitor | |||
| 0.178 | 0.018 | 0.178 | Protein kinase A inhibitor | |||
| 0.185 | 0.026 | 0.185 | Cyclin-dependent kinase 9 inhibitor | |||
| 0.169 | 0.01 | 0.169 | Glutamate (mGluR group I) antagonist | |||
| 0.196 | 0.037 | 0.196 | Toll-Like receptor 9 antagonist | |||
| 0.179 | 0.021 | 0.179 | Polo-like kinase-4 inhibitor | |||
| 0.187 | 0.03 | 0.187 | MAP kinase 3 inhibitor | |||
| 0.201 | 0.043 | 0.269 | Phospholipase C inhibitor | 0.269 0.022 DBMET00709 | DBMET00709 | |
| 0.219 | 0.062 | 0.219 | Tyrosine kinase inhibitor | |||
| 0.164 | 0.008 | 0.164 | MAP-kinase-activated kinase 2 inhibitor | |||
| 0.189 | 0.034 | 0.189 | Toll-Like receptor antagonist | |||
| 0.267 | 0.115 | 0.267 | Transcription factor NF kappa B inhibitor | |||
| 0.169 | 0.016 | 0.169 | Nitric-oxide synthase inhibitor | 0.094 0.07 DBMET00709 | ||
| 0.29 | 0.138 | 0.306 | 15-Lipoxygenase inhibitor | 0.306 0.128 DBMET00709 | DBMET00709 | |
| 0.165 | 0.013 | 0.165 | I kappa B kinase inhibitor | |||
| 0.173 | 0.023 | 0.173 | UDP-glucose 4-epimerase inhibitor | 0.17 0.023 DBMET00708 | ||
| 0.18 | 0.029 | 0.18 | Cathepsin H inhibitor | |||
| 0.191 | 0.041 | 0.191 | Arachidonic acid antagonist | 0.141 0.099 DBMET00708 | ||
| 0.169 | 0.023 | 0.169 | MAP kinase 8 inhibitor | |||
| 0.195 | 0.05 | 0.195 | Cytidine deaminase inhibitor | |||
| 0.22 | 0.075 | 0.22 | EphB2 antagonist | |||
| 0.15 | 0.005 | 0.15 | Granulocyte macrophage colony stimulating factor agonist | 0.091 0.049 DBMET00708 | ||
| 0.162 | 0.017 | 0.162 | Protein kinase C delta inhibitor | |||
| 0.17 | 0.026 | 0.17 | Protein kinase (CK2) inhibitor | |||
| 0.185 | 0.042 | 0.185 | Cyclin-dependent kinase inhibitor | |||
| 0.162 | 0.021 | 0.162 | Ca2+-transporting ATPase inhibitor | 0.151 0.041 DBMET00708 | ||
| 0.144 | 0.004 | 0.144 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.076 0.045 DBMET00708 0.092 0.02 DBMET00709 | ||
| 0.206 | 0.066 | 0.206 | DNA methyltransferase I inhibitor | |||
| 0.166 | 0.027 | 0.166 | Check point kinase 2 inhibitor | |||
| 0.149 | 0.011 | 0.149 | Myeloperoxidase inhibitor | |||
| 0.148 | 0.01 | 0.148 | Biliverdin reductase inhibitor | 0.066 0.035 DBMET00708 | ||
| 0.178 | 0.041 | 0.317 | Cell wall synthesis inhibitor | 0.183 0.038 DBMET00708 0.317 0.009 DBMET00709 | DBMET00709 | |
| 0.174 | 0.038 | 0.174 | TRKA antagonist | |||
| 0.186 | 0.051 | 0.186 | Growth factor antagonist | |||
| 0.181 | 0.048 | 0.181 | RET inhibitor | |||
| 0.137 | 0.005 | 0.137 | Bombesin 3 receptor antagonist | |||
| 0.146 | 0.014 | 0.146 | Nav1.8 sodium channel blocker | 0.073 0.052 DBMET00708 0.071 0.055 DBMET00709 | ||
| 0.139 | 0.007 | 0.139 | Alpha 2 adrenoreceptor agonist | |||
| 0.201 | 0.07 | 0.201 | Non-steroidal antiinflammatory agent | |||
| 0.188 | 0.057 | 0.188 | Heat shock protein 90 alpha antagonist | |||
| 0.151 | 0.021 | 0.151 | DOPA decarboxylase inhibitor | 0.123 0.041 DBMET00708 | ||
| 0.136 | 0.005 | 0.136 | Topoisomerase II beta inhibitor | |||
| 0.161 | 0.031 | 0.161 | GABA receptor agonist | |||
| 0.181 | 0.053 | 0.181 | Protein-tyrosine kinase Lyn inhibitor | |||
| 0.141 | 0.012 | 0.141 | Carbamoyl phosphate synthetase inhibitor | 0.073 0.032 DBMET00708 0.083 0.027 DBMET00709 | ||
| 0.138 | 0.01 | 0.138 | Nicotinic alpha4beta2 receptor antagonist | |||
| 0.135 | 0.008 | 0.135 | Glutamate (mGluR1) antagonist | |||
| 0.173 | 0.046 | 0.173 | Cyclin-dependent kinase 7 inhibitor | |||
| 0.136 | 0.011 | 0.136 | Protein kinase C iota inhibitor | |||
| 0.13 | 0.005 | 0.13 | Potassium channel small-conductance Ca-activated blocker | |||
| 0.143 | 0.018 | 0.143 | Inducible nitric-oxide synthase inhibitor | 0.099 0.038 DBMET00709 | ||
| 0.185 | 0.062 | 0.185 | Src kinase inhibitor | |||
| 0.17 | 0.049 | 0.17 | Cytokine production inhibitor | |||
| 0.149 | 0.028 | 0.149 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | |||
| 0.14 | 0.02 | 0.14 | Phosphofructokinase-1 inhibitor | 0.083 0.039 DBMET00708 0.07 0.048 DBMET00709 | ||
| 0.154 | 0.035 | 0.154 | Falcipain 3 inhibitor | |||
| 0.151 | 0.033 | 0.151 | Papain-like protease (SARS coronavirus) inhibitor | |||
| 0.174 | 0.055 | 0.174 | Acetylcholine M1 receptor antagonist | |||
| 0.168 | 0.05 | 0.45 | Hemostatic | 0.45 0.005 DBMET00709 | DBMET00709 | |
| 0.145 | 0.026 | 0.145 | Creatine kinase inhibitor | 0.137 0.03 DBMET00708 0.11 0.049 DBMET00709 | ||
| 0.15 | 0.031 | 0.15 | DNA repair enzyme inhibitor | |||
| 0.126 | 0.008 | 0.126 | Potassium channel (ATP-sensitive) blocker | |||
| 0.171 | 0.053 | 0.171 | Tyrosine-protein kinase receptor antagonist | |||
| 0.142 | 0.024 | 0.142 | Phosphodiesterase 7B inhibitor | |||
| 0.139 | 0.021 | 0.139 | MAP kinase 14 inhibitor | |||
| 0.135 | 0.017 | 0.135 | Rho-associated kinase I inhibitor | |||
| 0.199 | 0.081 | 0.199 | Pyruvate kinase inhibitor | 0.18 0.093 DBMET00708 | ||
| 0.154 | 0.037 | 0.154 | Alpha 2b adrenoreceptor antagonist | |||
| 0.154 | 0.037 | 0.154 | Heat shock protein 70 antagonist | |||
| 0.122 | 0.004 | 0.153 | Sodium/calcium exchanger inhibitor | 0.153 0.004 DBMET00709 | DBMET00709 | |
| 0.156 | 0.041 | 0.156 | Platelet activating factor antagonist | |||
| 0.138 | 0.024 | 0.138 | Carbonic anhydrase VI inhibitor | 0.079 0.058 DBMET00708 0.092 0.045 DBMET00709 | ||
| 0.135 | 0.021 | 0.135 | Acetylcholine nicotinic agonist | |||
| 0.119 | 0.006 | 0.119 | Aconitate hydratase inhibitor | 0.053 0.034 DBMET00708 | ||
| 0.179 | 0.065 | 0.179 | MAP kinase kinase 5 inhibitor | |||
| 0.159 | 0.046 | 0.159 | MAP kinase kinase 4 inhibitor | |||
| 0.124 | 0.012 | 0.124 | D-Ala-D-Ala ligase inhibitor | 0.092 0.041 DBMET00708 | ||
| 0.125 | 0.014 | 0.125 | GABA aminotransferase inhibitor | |||
| 0.127 | 0.016 | 0.127 | Aromatase inhibitor | 0.068 0.035 DBMET00709 | ||
| 0.155 | 0.045 | 0.155 | Interleukin 4 antagonist | |||
| 0.125 | 0.014 | 0.125 | CDC7 inhibitor | |||
| 0.115 | 0.005 | 0.115 | Glutamate (mGluR7) antagonist | |||
| 0.146 | 0.037 | 0.146 | MAP kinase kinase kinase inhibitor | |||
| 0.17 | 0.063 | 0.17 | Neurotensin receptor agonist | 0.158 0.084 DBMET00708 | ||
| 0.116 | 0.01 | 0.116 | 5 Hydroxytryptamine 3 agonist | |||
| 0.114 | 0.008 | 0.114 | Glutamate (mGluR group III) agonist | |||
| 0.126 | 0.021 | 0.126 | Glutamate dehydrogenase inhibitor | 0.077 0.048 DBMET00708 0.073 0.052 DBMET00709 | ||
| 0.119 | 0.016 | 0.119 | Protein kinase B beta inhibitor | |||
| 0.221 | 0.118 | 0.221 | Gastrin inhibitor | |||
| 0.115 | 0.013 | 0.115 | Purinergic P2X1 antagonist | 0.055 0.052 DBMET00708 0.057 0.048 DBMET00709 | ||
| 0.115 | 0.013 | 0.115 | Acyl-CoA dehydrogenase inhibitor | |||
| 0.129 | 0.028 | 0.306 | Triose-phosphate isomerase inhibitor | 0.097 0.051 DBMET00708 0.306 0.005 DBMET00709 | DBMET00709 | |
| 0.142 | 0.041 | 0.179 | Aminopeptidase B inhibitor | 0.086 0.076 DBMET00708 0.179 0.027 DBMET00709 | DBMET00709 | |
| 0.107 | 0.006 | 0.107 | Exportin-1 inhibitor | |||
| 0.225 | 0.124 | 0.225 | Hypoxia-inducible factor 1 alpha inhibitor | |||
| 0.163 | 0.062 | 0.163 | Heat shock protein 90 antagonist | |||
| 0.151 | 0.051 | 0.151 | Pregnane X receptor agonist | 0.131 0.097 DBMET00709 | ||
| 0.112 | 0.012 | 0.112 | Pim-2 kinase inhibitor | |||
| 0.115 | 0.016 | 0.115 | Argininosuccinate synthase inhibitor | 0.077 0.027 DBMET00708 | ||
| 0.158 | 0.06 | 0.158 | Amylase inhibitor | |||
| 0.127 | 0.03 | 0.127 | Alcohol dehydrogenase inhibitor | |||
| 0.11 | 0.014 | 0.153 | Carbonic anhydrase VB inhibitor | 0.153 0.009 DBMET00709 | DBMET00709 | |
| 0.1 | 0.005 | 0.1 | Glutamate (mGluR1a) antagonist | |||
| 0.117 | 0.022 | 0.117 | Glutamate decarboxylase inhibitor | 0.091 0.035 DBMET00708 0.065 0.061 DBMET00709 | ||
| 0.108 | 0.013 | 0.108 | NMDA 2C receptor antagonist | 0.086 0.022 DBMET00709 | ||
| 0.123 | 0.029 | 0.123 | Acetylcholine nicotinic antagonist | |||
| 0.144 | 0.051 | 0.144 | Aldehyde dehydrogenase inhibitor | 0.101 0.096 DBMET00708 | ||
| 0.127 | 0.035 | 0.127 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.093 0.061 DBMET00708 | ||
| 0.103 | 0.011 | 0.103 | AMPA receptor antagonist | |||
| 0.099 | 0.007 | 0.099 | Epithelial sodium channel blocker | |||
| 0.121 | 0.03 | 0.121 | Polo-like kinase-1 inhibitor | |||
| 0.099 | 0.008 | 0.099 | Cyclin D1 inhibitor | 0.06 0.043 DBMET00708 | ||
| 0.142 | 0.052 | 0.142 | Death-associated protein kinase 1 inhibitor | |||
| 0.158 | 0.068 | 0.158 | Interferon gamma antagonist | |||
| 0.119 | 0.03 | 0.261 | Carbonic anhydrase XIII inhibitor | 0.261 0.008 DBMET00709 | DBMET00709 | |
| 0.109 | 0.021 | 0.109 | Neuronal nicotinic receptor antagonist | |||
| 0.093 | 0.005 | 0.093 | Dihydropteroate synthase inhibitor | 0.035 0.034 DBMET00709 | ||
| 0.133 | 0.045 | 0.133 | Cyclin-dependent kinase 2 inhibitor | |||
| 0.132 | 0.044 | 0.132 | Photosensitizer | |||
| 0.144 | 0.057 | 0.144 | Vascular endothelial growth factor antagonist | |||
| 0.14 | 0.053 | 0.14 | Protein-tyrosine kinase (PTK, not ETK, WZC) inhibitor | |||
| 0.14 | 0.053 | 0.14 | Abl kinase inhibitor | |||
| 0.103 | 0.017 | 0.103 | Secretase beta inhibitor | |||
| 0.11 | 0.024 | 0.11 | Protein kinase B alpha inhibitor | |||
| 0.099 | 0.013 | 0.099 | MAP kinase kinase 7 inhibitor | 0.085 0.033 DBMET00708 | ||
| 0.098 | 0.013 | 0.098 | I kappa B kinase 2 inhibitor | |||
| 0.109 | 0.024 | 0.109 | Alpha adrenoreceptor agonist | |||
| 0.115 | 0.03 | 0.115 | Phosphodiesterase 6D inhibitor | |||
| 0.111 | 0.027 | 0.218 | NMDA 2 receptor antagonist | 0.218 0.008 DBMET00709 | DBMET00709 | |
| 0.094 | 0.011 | 0.094 | Botulinum neurotoxin type A inhibitor | |||
| 0.145 | 0.063 | 0.145 | Alkaline phosphatase inhibitor | 0.131 0.074 DBMET00709 | ||
| 0.114 | 0.032 | 0.114 | Platelet growth factor antagonist | |||
| 0.122 | 0.04 | 0.122 | CDC-like kinase 3 inhibitor | |||
| 0.2 | 0.119 | 0.2 | Neuropeptide Y2 antagonist | |||
| 0.12 | 0.039 | 0.12 | Folate antagonist | |||
| 0.107 | 0.026 | 0.107 | mTOR complex 2 inhibitor | |||
| 0.127 | 0.046 | 0.127 | Nav1.5 sodium channel blocker | |||
| 0.108 | 0.028 | 0.108 | Histamine H2 receptor antagonist | |||
| 0.084 | 0.004 | 0.084 | Geranyltranstransferase inhibitor | |||
| 0.188 | 0.108 | 0.188 | Antiamyloidogenic | |||
| 0.1 | 0.021 | 0.1 | Glycine receptor agonist | |||
| 0.089 | 0.011 | 0.089 | Transcription factor RelA inhibitor | |||
| 0.093 | 0.015 | 0.093 | MAP kinase 7 inhibitor | |||
| 0.102 | 0.026 | 0.102 | Adenosine A3 receptor antagonist | |||
| 0.081 | 0.005 | 0.081 | Potassium channel Kv1.1 blocker | |||
| 0.106 | 0.03 | 0.106 | Protein kinase B gamma inhibitor | |||
| 0.08 | 0.005 | 0.08 | Alpha 1d adrenoreceptor agonist | 0.035 0.032 DBMET00708 | ||
| 0.139 | 0.064 | 0.162 | Cyclooxygenase 1 inhibitor | 0.162 0.051 DBMET00709 | DBMET00709 | |
| 0.089 | 0.014 | 0.089 | Carbonic anhydrase XIV inhibitor | |||
| 0.102 | 0.027 | 0.102 | Interferon agonist | 0.087 0.042 DBMET00709 | ||
| 0.117 | 0.042 | 0.133 | Anabolic | 0.093 0.073 DBMET00708 0.133 0.028 DBMET00709 | DBMET00709 | |
| 0.081 | 0.007 | 0.081 | Histamine H2 receptor agonist | |||
| 0.138 | 0.065 | 0.138 | Sodium channel (voltage-gated) blocker | |||
| 0.077 | 0.004 | 0.077 | Nerve growth factor antagonist | |||
| 0.1 | 0.028 | 0.1 | Aminopeptidase I inhibitor | |||
| 0.134 | 0.062 | 0.134 | Cyclooxygenase 3 inhibitor | |||
| 0.116 | 0.045 | 0.116 | Insulin receptor antagonist | |||
| 0.098 | 0.028 | 0.098 | Adenosine A2 receptor antagonist | |||
| 0.097 | 0.026 | 0.162 | Carbonic anhydrase VA inhibitor | 0.162 0.009 DBMET00709 | DBMET00709 | |
| 0.093 | 0.022 | 0.1 | GABA B receptor agonist | 0.1 0.016 DBMET00708 | DBMET00708 | |
| 0.085 | 0.015 | 0.085 | Toll-Like receptor 8 antagonist | |||
| 0.133 | 0.063 | 0.133 | Antibacterial (Helicobacter pylori) | 0.114 0.09 DBMET00709 | ||
| 0.104 | 0.034 | 0.104 | GABA A receptor agonist | |||
| 0.097 | 0.027 | 0.097 | Benzodiazepine agonist | |||
| 0.106 | 0.038 | 0.106 | Phosphodiesterase I inhibitor | |||
| 0.074 | 0.006 | 0.074 | Glutamate (mGluR4) agonist | |||
| 0.073 | 0.004 | 0.073 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.065 0.005 DBMET00708 0.051 0.014 DBMET00709 | ||
| 0.137 | 0.069 | 0.137 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | |||
| 0.108 | 0.04 | 0.108 | Potassium channel activator | |||
| 0.073 | 0.005 | 0.073 | Vascular adhesion protein 1 inhibitor | |||
| 0.102 | 0.034 | 0.102 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | |||
| 0.093 | 0.026 | 0.093 | Protein kinase C alpha inhibitor | |||
| 0.086 | 0.019 | 0.086 | Glutamate (mGluR6) antagonist | |||
| 0.094 | 0.027 | 0.094 | Adenosine A2a receptor antagonist | |||
| 0.128 | 0.061 | 0.128 | Alkylator | 0.11 0.078 DBMET00709 | ||
| 0.078 | 0.012 | 0.078 | Dihydroorotate oxidase inhibitor | 0.066 0.021 DBMET00708 | ||
| 0.192 | 0.125 | 0.297 | Immunostimulant | 0.297 0.079 DBMET00709 | DBMET00709 | |
| 0.073 | 0.007 | 0.073 | Dopamine beta hydroxylase inhibitor | 0.058 0.017 DBMET00708 | ||
| 0.085 | 0.019 | 0.512 | NMDA 2B receptor antagonist | 0.512 0.003 DBMET00709 | DBMET00709 | |
| 0.135 | 0.07 | 0.135 | Sodium channel blocker | |||
| 0.125 | 0.06 | 0.125 | Aurora-B kinase inhibitor | |||
| 0.076 | 0.011 | 0.076 | Ryanodine receptor antagonist | 0.067 0.022 DBMET00708 | ||
| 0.094 | 0.029 | 0.217 | Carbonic anhydrase V inhibitor | 0.217 0.005 DBMET00709 | DBMET00709 | |
| 0.075 | 0.011 | 0.075 | Adenosine deaminase inhibitor | 0.063 0.018 DBMET00709 | ||
| 0.096 | 0.032 | 0.157 | Purinergic P2X2 antagonist | 0.157 0.01 DBMET00709 | DBMET00709 | |
| 0.112 | 0.048 | 0.112 | CDK2/cyclin A inhibitor | |||
| 0.113 | 0.05 | 0.186 | Gastric antisecretory | 0.186 0.015 DBMET00709 | DBMET00709 | |
| 0.082 | 0.019 | 0.082 | Heat shock protein 90 beta antagonist | |||
| 0.073 | 0.009 | 0.073 | Immunoglobulin Fc receptor antagonist | |||
| 0.087 | 0.025 | 0.087 | Histone deacetylase inhibitor | |||
| 0.067 | 0.005 | 0.067 | Glutamate (mGluR8) agonist | |||
| 0.086 | 0.024 | 0.086 | CDK9/cyclin T1 inhibitor | |||
| 0.088 | 0.026 | 0.088 | Adenosine A1 receptor antagonist | |||
| 0.098 | 0.036 | 0.098 | MAP kinase 10 inhibitor | |||
| 0.144 | 0.082 | 0.406 | Diuretic | 0.406 0.013 DBMET00709 | DBMET00709 | |
| 0.069 | 0.008 | 0.069 | Cytokine production stimulant | |||
| 0.071 | 0.01 | 0.071 | Glutamate (mGluR4) antagonist | |||
| 0.098 | 0.037 | 0.098 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | |||
| 0.218 | 0.157 | 0.366 | Antithrombotic | 0.366 0.059 DBMET00709 | DBMET00709 | |
| 0.081 | 0.02 | 0.081 | Phosphodiesterase 4C inhibitor | |||
| 0.076 | 0.016 | 0.076 | Transforming growth factor beta 1 antagonist | |||
| 0.071 | 0.011 | 0.071 | Fructose-1,6-bisphosphatase inhibitor | |||
| 0.077 | 0.017 | 0.077 | MAP kinase kinase 9 inhibitor | |||
| 0.065 | 0.006 | 0.065 | Histamine H1 receptor agonist | |||
| 0.079 | 0.02 | 0.079 | Phosphodiesterase 1C inhibitor | |||
| 0.105 | 0.047 | 0.105 | Potassium channel (Voltage-sensitive) activator | |||
| 0.075 | 0.016 | 0.075 | Histamine agonist | |||
| 0.119 | 0.061 | 0.119 | Transcription factor STAT6 inhibitor | |||
| 0.115 | 0.057 | 0.115 | Aurora-A kinase inhibitor | |||
| 0.083 | 0.026 | 0.083 | NMDA receptor glycine site agonist | |||
| 0.119 | 0.062 | 0.119 | Microtubule formation inhibitor | |||
| 0.118 | 0.061 | 0.118 | Vascular endothelial growth factor 2 antagonist | |||
| 0.112 | 0.055 | 0.112 | Mediator release inhibitor | |||
| 0.08 | 0.023 | 0.08 | Interferon inducer | 0.073 0.03 DBMET00709 | ||
| 0.068 | 0.011 | 0.068 | Urate transporter 1 inhibitor | |||
| 0.107 | 0.05 | 0.107 | Potassium channel (Ca-activated) activator | |||
| 0.083 | 0.027 | 0.088 | NMDA receptor agonist | 0.088 0.024 DBMET00709 | DBMET00709 | |
| 0.15 | 0.094 | 0.15 | Antipruritic | |||
| 0.065 | 0.008 | 0.065 | Diamine oxidase inhibitor | |||
| 0.129 | 0.073 | 0.129 | CC chemokine 6 receptor antagonist | 0.121 0.115 DBMET00708 | ||
| 0.101 | 0.045 | 0.101 | Acetylcholine agonist | |||
| 0.166 | 0.11 | 0.166 | Platelet aggregation inhibitor | |||
| 0.116 | 0.061 | 0.116 | CDK3/cyclin E inhibitor | |||
| 0.074 | 0.019 | 0.074 | Nicotinic receptor alpha7 subunit antagonist | |||
| 0.063 | 0.008 | 0.063 | Potassium channel small-conductance Ca-activated activator | |||
| 0.084 | 0.029 | 0.098 | Phospholipase D inhibitor | 0.098 0.016 DBMET00709 | DBMET00709 | |
| 0.138 | 0.084 | 0.138 | Neuropeptide Y1 antagonist | |||
| 0.063 | 0.009 | 0.063 | Dihydrofolate reductase inhibitor | 0.059 0.011 DBMET00709 | ||
| 0.112 | 0.059 | 0.112 | Cyclin-dependent kinase 1 inhibitor | |||
| 0.058 | 0.004 | 0.058 | Nicotinic alpha3beta4 receptor agonist | |||
| 0.067 | 0.014 | 0.067 | Phosphodiesterase 7A inhibitor | |||
| 0.079 | 0.026 | 0.079 | Carbonic anhydrase stimulant | |||
| 0.099 | 0.046 | 0.099 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | |||
| 0.099 | 0.047 | 0.099 | Insulin growth factor antagonist | |||
| 0.076 | 0.023 | 0.076 | GABA A receptor antagonist | |||
| 0.102 | 0.05 | 0.102 | Interleukin 12 antagonist | |||
| 0.124 | 0.072 | 0.124 | c-Src kinase inhibitor | |||
| 0.064 | 0.011 | 0.064 | Glutamate (mGluR group III) antagonist | |||
| 0.075 | 0.023 | 0.075 | Ornithine carbamoyltransferase inhibitor | |||
| 0.075 | 0.023 | 0.075 | GABA receptor antagonist | |||
| 0.065 | 0.013 | 0.065 | CDK5/p25 inhibitor | |||
| 0.111 | 0.06 | 0.111 | Granulocyte macrophage colony stimulating factor antagonist | |||
| 0.065 | 0.014 | 0.065 | Thymidylate synthase inhibitor | |||
| 0.072 | 0.021 | 0.072 | Protein kinase C theta inhibitor | |||
| 0.104 | 0.053 | 0.104 | Protein kinase C mu inhibitor | |||
| 0.063 | 0.013 | 0.063 | AICAR transformylase inhibitor | |||
| 0.09 | 0.04 | 0.09 | Estrogen-related receptor beta agonist | 0.082 0.061 DBMET00708 | ||
| 0.065 | 0.015 | 0.065 | Histamine H4 receptor antagonist | |||
| 0.102 | 0.053 | 0.102 | Prolactin inhibitor | 0.101 0.055 DBMET00708 | ||
| 0.097 | 0.048 | 0.097 | Phosphodiesterase IV inhibitor | |||
| 0.084 | 0.036 | 0.084 | CDK2/cyclin E2 inhibitor | |||
| 0.077 | 0.028 | 0.077 | Phosphodiesterase VII inhibitor | |||
| 0.067 | 0.019 | 0.067 | Potassium channel (Inward rectifier) blocker | |||
| 0.054 | 0.006 | 0.054 | Protein kinase (CK2) beta inhibitor | |||
| 0.108 | 0.059 | 0.108 | Alpha 2c adrenoreceptor antagonist | |||
| 0.091 | 0.043 | 0.091 | NAD(P)H dehydrogenase (quinone) inhibitor | |||
| 0.125 | 0.078 | 0.129 | Nav1.2 sodium channel blocker | 0.129 0.073 DBMET00709 | DBMET00709 | |
| 0.063 | 0.016 | 0.063 | Adenylate cyclase 1 inhibitor | |||
| 0.055 | 0.008 | 0.055 | Hypoxanthine phosphoribosyltransferase inhibitor | |||
| 0.072 | 0.025 | 0.072 | Histone deacetylase SIRT3 inhibitor | |||
| 0.14 | 0.093 | 0.14 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | |||
| 0.111 | 0.064 | 0.114 | DNA intercalator | 0.114 0.061 DBMET00709 | DBMET00709 | |
| 0.074 | 0.027 | 0.074 | Cyclin-dependent kinase 6 inhibitor | |||
| 0.055 | 0.009 | 0.055 | Heme oxygenase inhibitor | |||
| 0.094 | 0.048 | 0.094 | Bromodomain-containing protein 2 inhibitor | 0.082 0.073 DBMET00708 | ||
| 0.071 | 0.025 | 0.071 | Gonadotropin-releasing hormone receptor agonist | |||
| 0.055 | 0.01 | 0.055 | Glutamate (mGluR3) antagonist | |||
| 0.135 | 0.09 | 0.135 | Sphingosine 1-phosphate receptor 5 antagonist | 0.135 0.089 DBMET00708 | ||
| 0.198 | 0.153 | 0.198 | 12-Lipoxygenase inhibitor | |||
| 0.078 | 0.033 | 0.078 | Protein kinase C beta inhibitor | |||
| 0.087 | 0.043 | 0.087 | T cell inhibitor | |||
| 0.064 | 0.02 | 0.064 | Nicotinic receptor alpha4 subunit antagonist | |||
| 0.092 | 0.048 | 0.092 | Insulin like growth factor 1 antagonist | |||
| 0.18 | 0.136 | 0.18 | Spasmolytic | |||
| 0.065 | 0.022 | 0.065 | Lysine-specific demethylase 1A inhibitor | |||
| 0.056 | 0.012 | 0.056 | Phosphoglycerate kinase inhibitor | 0.054 0.013 DBMET00709 | ||
| 0.048 | 0.005 | 0.048 | Nicotinic alpha4beta2 receptor agonist | |||
| 0.068 | 0.025 | 0.068 | Cyclin A1 inhibitor | |||
| 0.08 | 0.038 | 0.08 | Check point kinase 1 inhibitor | |||
| 0.05 | 0.008 | 0.05 | ATR kinase inhibitor | |||
| 0.076 | 0.034 | 0.076 | Cyclin A2 inhibitor | |||
| 0.061 | 0.019 | 0.061 | Potassium channel (Inward rectifier) activator | |||
| 0.09 | 0.048 | 0.09 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | |||
| 0.07 | 0.028 | 0.07 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.16 | 0.118 | 0.16 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | |||
| 0.063 | 0.022 | 0.063 | Adenosine A2b receptor antagonist | |||
| 0.071 | 0.03 | 0.071 | Xanthine dehydrogenase inhibitor | |||
| 0.045 | 0.005 | 0.045 | MAP3K8 inhibitor | |||
| 0.08 | 0.04 | 0.08 | MAP3K7 inhibitor | |||
| 0.058 | 0.018 | 0.058 | Potassium channel (ATP-sensitive) activator | |||
| 0.077 | 0.038 | 0.077 | Tyk2 inhibitor | |||
| 0.098 | 0.059 | 0.116 | Fibroblast growth factor 1 antagonist | 0.116 0.045 DBMET00709 | DBMET00709 | |
| 0.049 | 0.01 | 0.049 | Endothelial nitric-oxide synthase inhibitor | |||
| 0.064 | 0.025 | 0.064 | mTOR inhibitor | |||
| 0.074 | 0.035 | 0.074 | Cyclin A inhibitor | |||
| 0.082 | 0.044 | 0.082 | Acetylcholine M4 receptor antagonist | |||
| 0.086 | 0.048 | 0.086 | Glutamate receptor agonist | |||
| 0.072 | 0.035 | 0.072 | Aryl hydrocarbon receptor antagonist | |||
| 0.065 | 0.027 | 0.065 | Phosphodiesterase 4A inhibitor | |||
| 0.051 | 0.014 | 0.051 | AMPA 4 receptor antagonist | |||
| 0.043 | 0.005 | 0.043 | Purinergic P2Y15 antagonist | |||
| 0.096 | 0.059 | 0.096 | Proto-oncogene tyrosine-protein kinase Kit inhibitor | |||
| 0.066 | 0.029 | 0.066 | Phosphodiesterase 1A inhibitor | |||
| 0.106 | 0.069 | 0.106 | Mucolytic | |||
| 0.089 | 0.052 | 0.089 | Bcr-Abl kinase inhibitor | |||
| 0.057 | 0.021 | 0.057 | Glucose-6-phosphate isomerase inhibitor | 0.05 0.03 DBMET00708 | ||
| 0.066 | 0.03 | 0.066 | Prolactin release inhibitor | |||
| 0.053 | 0.017 | 0.053 | GABA B receptor antagonist | |||
| 0.067 | 0.031 | 0.067 | Potassium channel intermediate-conductance Ca-activated blocker | |||
| 0.086 | 0.05 | 0.086 | TIE-2 antagonist | |||
| 0.059 | 0.023 | 0.059 | Lysophosphatidic acid 3 receptor antagonist | |||
| 0.088 | 0.052 | 0.088 | TIE antagonist | |||
| 0.061 | 0.026 | 0.061 | Thromboxane synthase inhibitor | |||
| 0.085 | 0.05 | 0.085 | Caspase 7 inhibitor | |||
| 0.054 | 0.019 | 0.054 | Kainate receptor antagonist | |||
| 0.05 | 0.015 | 0.05 | Inosine monophosphate dehydrogenase inhibitor | |||
| 0.082 | 0.047 | 0.082 | Keratolytic | 0.071 0.062 DBMET00708 | ||
| 0.098 | 0.064 | 0.098 | Platelet activating factor beta antagonist | |||
| 0.079 | 0.045 | 0.079 | Telomerase inhibitor | |||
| 0.048 | 0.014 | 0.048 | Protein kinase (CK1) epsilon inhibitor | |||
| 0.079 | 0.045 | 0.079 | Raf kinase inhibitor | |||
| 0.063 | 0.028 | 0.063 | Sphingosine kinase 2 inhibitor | |||
| 0.051 | 0.017 | 0.054 | Dopamine D5 agonist | 0.054 0.015 DBMET00708 | DBMET00708 | |
| 0.048 | 0.014 | 0.048 | Fumarate hydratase inhibitor | |||
| 0.13 | 0.096 | 0.13 | Thiol protease inhibitor | |||
| 0.157 | 0.124 | 0.157 | Insulin sensitizer | |||
| 0.096 | 0.063 | 0.096 | Platelet activating factor alpha antagonist | |||
| 0.096 | 0.064 | 0.096 | Sphingomyelinase inhibitor | |||
| 0.061 | 0.029 | 0.061 | Phosphatidylinositol 3-kinase alpha inhibitor | |||
| 0.065 | 0.033 | 0.065 | 5 Hydroxytryptamine 6 antagonist | |||
| 0.036 | 0.004 | 0.036 | Cyclin T1 inhibitor | |||
| 0.108 | 0.076 | 0.108 | Anesthetic local | |||
| 0.064 | 0.032 | 0.064 | Sphingosine 1-phosphate receptor 3 antagonist | |||
| 0.097 | 0.066 | 0.097 | Glutamate (mGluR7) agonist | |||
| 0.129 | 0.097 | 0.129 | Cholinergic | |||
| 0.035 | 0.004 | 0.035 | Alpha 2c adrenoreceptor agonist | |||
| 0.047 | 0.016 | 0.047 | MAP3K5 inhibitor | |||
| 0.042 | 0.011 | 0.042 | Transforming growth factor beta 2 antagonist | |||
| 0.035 | 0.005 | 0.035 | Alpha 2a adrenoreceptor agonist | |||
| 0.04 | 0.01 | 0.04 | CDK4/cyclin D3 inhibitor | |||
| 0.083 | 0.053 | 0.083 | Adrenaline agonist | |||
| 0.089 | 0.06 | 0.089 | CDK/cyclin complex inhibitor | |||
| 0.107 | 0.078 | 0.107 | Adenylate cyclase inhibitor | |||
| 0.112 | 0.084 | 0.112 | TRKB antagonist | |||
| 0.056 | 0.028 | 0.056 | Proto-oncogene tyrosine-protein kinase Met inhibitor | |||
| 0.048 | 0.019 | 0.048 | Plasmepsin II inhibitor | |||
| 0.045 | 0.016 | 0.045 | Opioid delta receptor agonist | |||
| 0.087 | 0.059 | 0.087 | Interleukin 5 antagonist | |||
| 0.073 | 0.045 | 0.073 | Amidase inhibitor | |||
| 0.033 | 0.005 | 0.033 | Complement factor 1s inhibitor | |||
| 0.079 | 0.051 | 0.092 | Na+ K+ transporting ATPase inhibitor | 0.092 0.039 DBMET00709 | DBMET00709 | |
| 0.033 | 0.006 | 0.033 | Fructose-1,6-bisphosphatase 1 inhibitor | |||
| 0.04 | 0.012 | 0.04 | Methionyl aminopeptidase 1 inhibitor | |||
| 0.097 | 0.07 | 0.097 | Urease inhibitor | |||
| 0.041 | 0.014 | 0.041 | Acetylcholine M4 receptor agonist | |||
| 0.069 | 0.042 | 0.069 | 5 Hydroxytryptamine 3A antagonist | |||
| 0.077 | 0.05 | 0.077 | Phosphodiesterase 4D inhibitor | |||
| 0.059 | 0.033 | 0.059 | Pregnane X receptor antagonist | |||
| 0.047 | 0.021 | 0.047 | Histone deacetylase class I inhibitor | |||
| 0.082 | 0.056 | 0.082 | CC chemokine 5 receptor agonist | |||
| 0.069 | 0.042 | 0.069 | MDM2 inhibitor | |||
| 0.124 | 0.097 | 0.124 | Aurora-C kinase inhibitor | |||
| 0.04 | 0.015 | 0.04 | Tryptophan 5 hydroxylase inhibitor | |||
| 0.078 | 0.053 | 0.078 | Fibroblast growth factor 3 antagonist | |||
| 0.07 | 0.044 | 0.07 | Sphingosine 1-phosphate receptor 4 agonist | |||
| 0.045 | 0.02 | 0.045 | Kainate receptor agonist | |||
| 0.033 | 0.008 | 0.088 | Glutamate (mGluR1a) agonist | 0.088 0.004 DBMET00709 | DBMET00709 | |
| 0.05 | 0.025 | 0.05 | Glutamate (mGluR5) agonist | 0.046 0.031 DBMET00709 | ||
| 0.062 | 0.037 | 0.062 | EphB4 antagonist | |||
| 0.053 | 0.028 | 0.053 | Glutamate (mGluR group I) agonist | 0.044 0.037 DBMET00709 | ||
| 0.055 | 0.031 | 0.104 | H+/K+-transporting ATPase inhibitor | 0.104 0.008 DBMET00709 | DBMET00709 | |
| 0.063 | 0.039 | 0.063 | Raf kinase B inhibitor | |||
| 0.042 | 0.018 | 0.042 | Integrin alpha2 antagonist | |||
| 0.03 | 0.006 | 0.03 | ICAM 1 antagonist | |||
| 0.035 | 0.011 | 0.035 | 5 Hydroxytryptamine 6 agonist | |||
| 0.075 | 0.051 | 0.075 | Phosphodiesterase VI inhibitor | |||
| 0.032 | 0.009 | 0.032 | Hedgehog signaling activator | |||
| 0.044 | 0.021 | 0.044 | Glutamate (mGluR group II) antagonist | |||
| 0.058 | 0.035 | 0.058 | Phosphatidylinositol 3-kinase gamma inhibitor | |||
| 0.033 | 0.012 | 0.033 | Dopamine autoreceptor agonist | |||
| 0.037 | 0.015 | 0.037 | AMPA 3 receptor antagonist | |||
| 0.033 | 0.012 | 0.033 | Methionyl aminopeptidase 2 inhibitor | |||
| 0.074 | 0.052 | 0.074 | Janus tyrosine kinase 2 inhibitor | |||
| 0.032 | 0.01 | 0.032 | Integrin alpha2beta1 antagonist | |||
| 0.058 | 0.037 | 0.058 | Nicotinic neuronal receptor agonist | |||
| 0.106 | 0.085 | 0.106 | Acetylcholine antagonist | |||
| 0.087 | 0.066 | 0.104 | Hepatocyte growth factor antagonist | 0.104 0.048 DBMET00708 | DBMET00708 | |
| 0.079 | 0.058 | 0.079 | Leucine-rich repeat kinase 2 inhibitor | |||
| 0.073 | 0.052 | 0.073 | Histone deacetylase SIRT2 inhibitor | |||
| 0.042 | 0.021 | 0.042 | Kainate receptor 2 antagonist | |||
| 0.1 | 0.079 | 0.1 | Tyrosine-protein kinase receptor FLT3 inhibitor | |||
| 0.036 | 0.016 | 0.036 | Nicotinamide phosphoribosyltransferase inhibitor | |||
| 0.107 | 0.087 | 0.107 | Cholinergic antagonist | |||
| 0.055 | 0.034 | 0.066 | Alpha-mannosidase inhibitor | 0.056 0.033 DBMET00708 0.066 0.02 DBMET00709 | DBMET00709 | |
| 0.031 | 0.011 | 0.031 | Glucosylceramidase stimulant | |||
| 0.07 | 0.05 | 0.07 | Syk tyrosine kinase inhibitor | |||
| 0.061 | 0.041 | 0.061 | Enoyl-[acyl-carrier-protein] reductase inhibitor | |||
| 0.073 | 0.053 | 0.073 | Potassium channel (Tandem pore domain) blocker | |||
| 0.049 | 0.03 | 0.049 | Glutamate (mGluR5) antagonist | |||
| 0.033 | 0.014 | 0.033 | Lysine carboxypeptidase inhibitor | |||
| 0.057 | 0.038 | 0.057 | Ribonucleotide reductase inhibitor | |||
| 0.092 | 0.073 | 0.092 | Bronchodilator | |||
| 0.024 | 0.005 | 0.024 | Nicotinic alpha4 receptor agonist | |||
| 0.055 | 0.037 | 0.055 | Ribonucleoside-diphosphate reductase inhibitor | |||
| 0.027 | 0.009 | 0.027 | Inosine monophosphate dehydrogenase 2 inhibitor | |||
| 0.06 | 0.042 | 0.06 | Phosphodiesterase 1B inhibitor | |||
| 0.034 | 0.016 | 0.034 | Cyclin E2 inhibitor | |||
| 0.04 | 0.023 | 0.04 | DNA gyrase subunit B inhibitor | |||
| 0.059 | 0.041 | 0.059 | Phosphatidylinositol kinase inhibitor | |||
| 0.052 | 0.035 | 0.052 | 5 Hydroxytryptamine 4 antagonist | |||
| 0.025 | 0.008 | 0.025 | Histamine H4 receptor agonist | |||
| 0.101 | 0.085 | 0.101 | Topoisomerase II inhibitor | |||
| 0.021 | 0.005 | 0.021 | CDK2/cyclin A3 inhibitor | |||
| 0.042 | 0.026 | 0.042 | Thymidine kinase inhibitor | |||
| 0.022 | 0.006 | 0.022 | Complement factor D inhibitor | |||
| 0.031 | 0.015 | 0.031 | Histone deacetylase 1 inhibitor | |||
| 0.118 | 0.102 | 0.118 | Sphingosine 1-phosphate receptor 2 antagonist | |||
| 0.114 | 0.099 | 0.114 | Protein kinase stimulant | |||
| 0.09 | 0.075 | 0.09 | Bile acid receptor antagonist | |||
| 0.032 | 0.017 | 0.032 | Glutamate (mGluR2) antagonist | |||
| 0.064 | 0.05 | 0.087 | MAP kinase kinase 10 inhibitor | 0.087 0.024 DBMET00709 | DBMET00709 | |
| 0.03 | 0.015 | 0.052 | Kynurenine 3 monooxygenase inhibitor | 0.052 0.006 DBMET00709 | DBMET00709 | |
| 0.03 | 0.016 | 0.03 | Estrogen-related receptor gamma antagonist | |||
| 0.048 | 0.033 | 0.048 | Antimetabolite | |||
| 0.088 | 0.074 | 0.088 | Ephrin antagonist | |||
| 0.035 | 0.021 | 0.035 | Calcium release-activated channel blocker | |||
| 0.04 | 0.026 | 0.04 | Membrane dipeptidase inhibitor | |||
| 0.058 | 0.044 | 0.058 | Acetylcholine M5 receptor antagonist | |||
| 0.031 | 0.018 | 0.031 | DNA topoisomerase IV inhibitor | |||
| 0.045 | 0.031 | 0.045 | Oleamide hydrolase inhibitor | |||
| 0.098 | 0.085 | 0.098 | 5 Hydroxytryptamine 2B antagonist | |||
| 0.059 | 0.046 | 0.059 | 5 Hydroxytryptamine 5A antagonist | |||
| 0.052 | 0.039 | 0.052 | Nicotinic alpha3beta2 receptor antagonist | |||
| 0.043 | 0.03 | 0.043 | Guanylate cyclase inhibitor | 0.042 0.03 DBMET00709 | ||
| 0.02 | 0.007 | 0.02 | CC chemokine 9 receptor antagonist | |||
| 0.034 | 0.021 | 0.034 | Carboxypeptidase B inhibitor | 0.031 0.027 DBMET00709 | ||
| 0.021 | 0.009 | 0.021 | Alpha 2b adrenoreceptor agonist | |||
| 0.039 | 0.026 | 0.039 | 5 Hydroxytryptamine 2B agonist | |||
| 0.032 | 0.019 | 0.032 | Epoxide hydrolase 1 inhibitor | |||
| 0.045 | 0.032 | 0.058 | Mannosidase inhibitor | 0.046 0.03 DBMET00708 0.058 0.018 DBMET00709 | DBMET00709 | |
| 0.05 | 0.037 | 0.05 | Beta 2 adrenoreceptor antagonist | |||
| 0.028 | 0.015 | 0.034 | Thymidine phosphorylase inhibitor | 0.034 0.009 DBMET00708 | DBMET00708 | |
| 0.035 | 0.023 | 0.035 | Adenosine uptake inhibitor | |||
| 0.063 | 0.052 | 0.063 | Phosphodiesterase 4B inhibitor | |||
| 0.054 | 0.043 | 0.054 | 5 Hydroxytryptamine 3 antagonist | |||
| 0.016 | 0.005 | 0.016 | Cyclin D2 inhibitor | |||
| 0.024 | 0.013 | 0.024 | Adenosine kinase inhibitor | |||
| 0.022 | 0.011 | 0.022 | Factor XIII inhibitor | |||
| 0.046 | 0.035 | 0.046 | Benzodiazepine antagonist | |||
| 0.053 | 0.042 | 0.053 | Beta 1 adrenoreceptor antagonist | |||
| 0.041 | 0.031 | 0.041 | Oxytocin agonist | |||
| 0.179 | 0.169 | 0.179 | Transcription factor STAT inhibitor | |||
| 0.022 | 0.012 | 0.022 | Steroid 17-alpha-hydroxylase/17,20 lyase inhibitor | |||
| 0.038 | 0.029 | 0.038 | Histone deacetylase 9 inhibitor | |||
| 0.041 | 0.032 | 0.041 | DNA gyrase subunit A inhibitor | |||
| 0.062 | 0.053 | 0.062 | Acetylcholine M5 receptor agonist | |||
| 0.045 | 0.036 | 0.045 | Aldosterone antagonist | |||
| 0.021 | 0.012 | 0.021 | Toll-Like receptor 8 agonist | |||
| 0.025 | 0.016 | 0.034 | Glutamate (mGluR1) agonist | 0.034 0.008 DBMET00709 | DBMET00709 | |
| 0.017 | 0.009 | 0.017 | Purinergic P2Y1 agonist | 0.015 0.011 DBMET00709 | ||
| 0.051 | 0.042 | 0.051 | Nicotinic alpha7 receptor agonist | |||
| 0.019 | 0.011 | 0.019 | Methylmalonyl-CoA mutase inhibitor | |||
| 0.085 | 0.077 | 0.085 | DNA directed RNA polymerase inhibitor | |||
| 0.022 | 0.014 | 0.022 | Glutaminyl-peptide cyclotransferase inhibitor | |||
| 0.029 | 0.021 | 0.029 | AMPA 1 receptor antagonist | |||
| 0.06 | 0.052 | 0.06 | Fibroblast growth factor 2 antagonist | |||
| 0.089 | 0.082 | 0.089 | Expectorant | |||
| 0.054 | 0.047 | 0.054 | 5 Hydroxytryptamine 5 antagonist | |||
| 0.098 | 0.092 | 0.098 | Histone deacetylase class III inhibitor | |||
| 0.016 | 0.01 | 0.016 | Adenosine A2a receptor agonist | |||
| 0.113 | 0.106 | 0.113 | Vanilloid 1 agonist | |||
| 0.027 | 0.02 | 0.035 | Uridine phosphorylase inhibitor | 0.035 0.014 DBMET00708 | DBMET00708 | |
| 0.017 | 0.011 | 0.017 | Adenosine A2 receptor agonist | |||
| 0.135 | 0.129 | 0.135 | ATPase inhibitor | |||
| 0.012 | 0.007 | 0.012 | Purine nucleoside phosphorylase inhibitor | |||
| 0.053 | 0.048 | 0.053 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | |||
| 0.033 | 0.028 | 0.033 | Arginase inhibitor | |||
| 0.037 | 0.031 | 0.037 | Vanilloid 3 antagonist | |||
| 0.015 | 0.01 | 0.015 | CXC chemokine 4 receptor agonist | |||
| 0.018 | 0.013 | 0.018 | Granulocyte colony stimulating factor receptor agonist | |||
| 0.017 | 0.012 | 0.017 | Nicotinic acid receptor 1 antagonist | |||
| 0.026 | 0.021 | 0.026 | Thymidine kinase (Herpes simplex virus 1) inhibitor | |||
| 0.064 | 0.06 | 0.104 | Catalase inhibitor | 0.104 0.037 DBMET00709 | DBMET00709 | |
| 0.022 | 0.018 | 0.022 | Isoleucine-tRNA ligase inhibitor | |||
| 0.031 | 0.027 | 0.031 | Histone deacetylase 2 inhibitor | |||
| 0.085 | 0.081 | 0.085 | Interleukin 1 beta converting enzyme inhibitor | |||
| 0.052 | 0.048 | 0.052 | Alpha 1 adrenoreceptor agonist | |||
| 0.007 | 0.004 | 0.007 | CC chemokine 6 receptor agonist | |||
| 0.05 | 0.047 | 0.05 | Glucosylceramidase inhibitor | |||
| 0.026 | 0.023 | 0.026 | Thrombin receptor antagonist | |||
| 0.019 | 0.016 | 0.019 | Imidazoline I1 receptor antagonist | |||
| 0.024 | 0.022 | 0.024 | Acid ceramidase inhibitor | |||
| 0.081 | 0.079 | 0.081 | Thioredoxin inhibitor | |||
| 0.106 | 0.104 | 0.106 | Sphingosine 1-phosphate receptor 4 antagonist | |||
| 0.025 | 0.023 | 0.025 | 5 Hydroxytryptamine 1D agonist | |||
| 0.005 | 0.003 | 0.005 | Reverse transcriptase (HBV) inhibitor | |||
| 0.033 | 0.031 | 0.033 | Potassium channel KCNQ activator | |||
| 0.033 | 0.031 | 0.033 | Delayed rectifier potassium channel activator | |||
| 0.065 | 0.064 | 0.065 | Alpha 2a adrenoreceptor antagonist | |||
| 0.033 | 0.032 | 0.033 | Factor XIIIa inhibitor | |||
| 0.174 | 0.173 | 0.174 | Transcription factor STAT3 inhibitor | |||
| 0.095 | 0.094 | 0.095 | Proteasome inhibitor | |||
| 0.012 | 0.011 | 0.012 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | |||
| 0.03 | 0.029 | 0.03 | Glutamate (mGluR3) agonist | |||
| 0.014 | 0.013 | 0.014 | NMDA receptor phencyclidine site antagonist | |||
| 0.018 | 0.017 | 0.018 | Antibiotic Anthracycline-like | |||
| 0.073 | 0.074 | 0.111 | NMDA receptor antagonist | 0.111 0.04 DBMET00709 | DBMET00709 | |
| 0.021 | 0.024 | 0.023 | Purinergic P2X agonist | 0.023 0.022 DBMET00709 | DBMET00709 | |
| 0.029 | 0.032 | 0.064 | Purinergic P2Y2 antagonist | 0.064 0.007 DBMET00709 | DBMET00709 | |
| 0.131 | 0.135 | 0.623 | Angiogenesis stimulant | 0.623 0.006 DBMET00709 | DBMET00709 | |
| 0.051 | 0.061 | 0.075 | Sphingosine kinase inhibitor | 0.075 0.02 DBMET00709 | DBMET00709 | |
| 0.058 | 0.073 | 0.129 | Thrombin inhibitor | 0.129 0.015 DBMET00709 | DBMET00709 | |
| 0.044 | 0.065 | 0.065 | Heparanase inhibitor | 0.065 0.016 DBMET00709 | DBMET00709 | |
| 0.086 | 0.109 | 0.124 | Cholesterol synthesis inhibitor | 0.124 0.062 DBMET00709 | DBMET00709 | |
| 0.03 | 0.058 | 0.069 | Leukocyte elastase inhibitor | 0.069 0.015 DBMET00709 | DBMET00709 | |
| 0.062 | 0.093 | 0.096 | Glycine receptor antagonist | 0.096 0.036 DBMET00709 | DBMET00709 | |
| 0.105 | 0.137 | 0.131 | Phospholipase A2 inhibitor | 0.131 0.099 DBMET00709 | DBMET00709 | |
| 0.038 | 0.073 | 0.099 | Carbonic anhydrase inhibitor | 0.099 0.027 DBMET00709 | DBMET00709 | |
| 0.024 | 0.062 | 0.106 | Factor Xa inhibitor | 0.106 0.013 DBMET00709 | DBMET00709 | |
| 0.008 | 0.05 | 0.019 | Sodium/hydrogen exchanger inhibitor | 0.019 0.009 DBMET00709 | DBMET00709 | |
| 0.118 | 0.166 | 0.199 | Antimitotic | 0.199 0.084 DBMET00709 | DBMET00709 | |
| 0.075 | 0.125 | 0.097 | Beta glucuronidase inhibitor | 0.097 0.074 DBMET00708 | DBMET00708 | |
| 0.034 | 0.087 | 0.132 | Factor IXa inhibitor | 0.132 0.005 DBMET00709 | DBMET00709 | |
| 0.062 | 0.146 | 0.129 | Chelator | 0.129 0.046 DBMET00708 | DBMET00708 | |
| 0.039 | 0.128 | 0.085 | Cathepsin G inhibitor | 0.085 0.04 DBMET00709 | DBMET00709 | |
| 0.049 | 0.152 | 0.073 | Chymotrypsin inhibitor | 0.073 0.065 DBMET00709 | DBMET00709 | |
| 0.016 | 0.142 | 0.057 | Factor XIa inhibitor | 0.057 0.014 DBMET00709 | DBMET00709 | |
| 0.012 | 0.139 | 0.115 | Dopamine D2 agonist | 0.115 0.009 DBMET00709 | DBMET00709 | |
| 0.073 | 0.207 | 0.607 | Anticoagulant | 0.607 0.005 DBMET00709 | DBMET00709 | |
| 0.01 | 0.166 | 0.057 | Factor XI inhibitor | 0.057 0.008 DBMET00709 | DBMET00709 | |
| 0.139 | 0.3 | 0.246 | Apoptosis antagonist | 0.246 0.132 DBMET00708 | DBMET00708 | |
| 0.042 | 0.231 | 0.094 | Breast cancer-resistant protein inhibitor | 0.094 0.062 DBMET00709 | DBMET00709 | |
| 0.044 | 0.255 | 0.259 | Multidrug resistance-associated protein 1 inhibitor | 0.259 0.005 DBMET00709 | DBMET00709 | |
| 0.006 | 0.221 | 0.028 | Dopamine D1 agonist | 0.028 0.01 DBMET00709 | DBMET00709 | |
| 0.044 | 0.261 | 0.219 | Thrombolytic | 0.219 0.043 DBMET00709 | DBMET00709 | |
| 0.016 | 0.24 | 0.318 | Selectin antagonist | 0.318 0.005 DBMET00709 | DBMET00709 | |
| 0.017 | 0.285 | 0.077 | Neuraminidase (influenza) inhibitor | 0.077 0.027 DBMET00709 | DBMET00709 | |
| 0.01 | 0.292 | 0.268 | HIV-1 integrase (Strand Transfer) inhibitor | 0.268 0.005 DBMET00709 | DBMET00709 | |
| 0.017 | 0.322 | 0.178 | CDC25A inhibitor | 0.178 0.009 DBMET00709 | DBMET00709 | |
| 0.036 | 0.362 | 0.149 | Nav1.4 sodium channel blocker | 0.149 0.034 DBMET00708 0.143 0.037 DBMET00709 | DBMET00708 | |
| 0.01 | 0.338 | 0.224 | HIV-1 integrase (3'-Processing) inhibitor | 0.224 0.008 DBMET00709 | DBMET00709 | |
| 0.038 | 0.371 | 0.422 | Dual specificity phosphatase 3 inhibitor | 0.32 0.025 DBMET00708 0.422 0.012 DBMET00709 | DBMET00709 | |
| 0.103 | 0.52 | 0.391 | Antiinflammatory | 0.391 0.144 DBMET00709 | DBMET00709 | |
| 0.029 | 0.458 | 0.417 | Dual specificity phosphatase inhibitor | 0.264 0.035 DBMET00708 0.417 0.013 DBMET00709 | DBMET00709 | |
| 0.006 | 0.438 | 0.123 | NMDA 2D receptor antagonist | 0.123 0.004 DBMET00709 | DBMET00709 | |
| 0.035 | 0.496 | 0.354 | Platelet adhesion inhibitor | 0.354 0.019 DBMET00709 | DBMET00709 | |
| 0.003 | 0.478 | 0.525 | Cholecystokinin A antagonist | 0.525 0.003 DBMET00709 | DBMET00709 | |
| 0.011 | 0.487 | 0.957 | Cholecystokinin B agonist | 0.957 0.001 DBMET00709 | DBMET00709 | |
| 0.004 | 0.49 | 0.043 | 1,3-Beta-glucan synthase inhibitor | 0.043 0.003 DBMET00709 | DBMET00709 | |
| 0.003 | 0.532 | 0.414 | Cholecystokinin B antagonist | 0.414 0.003 DBMET00709 | DBMET00709 | |
| 0.023 | 0.598 | 0.252 | Antioxidant | 0.238 0.091 DBMET00708 0.252 0.082 DBMET00709 | DBMET00709 | |
| 0.004 | 0.596 | 0.4 | Cholecystokinin antagonist | 0.4 0.003 DBMET00709 | DBMET00709 | |
| 0.017 | 0.619 | 0.151 | Platelet antagonist | 0.151 0.143 DBMET00709 | DBMET00709 | |
| 0.006 | 0.611 | 0.085 | Elastase inhibitor | 0.085 0.014 DBMET00709 | DBMET00709 | |
| 0.003 | 0.655 | 0.843 | Cholecystokinin A agonist | 0.843 0.001 DBMET00709 | DBMET00709 | |
| 0.003 | 0.663 | 0.856 | Cholecystokinin agonist | 0.856 0.001 DBMET00709 | DBMET00709 | |
| 0.005 | 0.719 | 0.085 | HIV-1 integrase inhibitor | 0.085 0.034 DBMET00709 | DBMET00709 | |
| 0.005 | 0.751 | 0.303 | Protein-tyrosine phosphatase inhibitor | 0.303 0.018 DBMET00709 | DBMET00709 | |
| 0.008 | 0.773 | 0.033 | Toll-Like receptor 4 agonist | 0.033 0.008 DBMET00709 | DBMET00709 | |
| 0.014 | 0.814 | 0.081 | Adenine nucleotide translocase inhibitor | 0.081 0.009 DBMET00709 | DBMET00709 | |
| 0.004 | 0.849 | 0.103 | Protein-tyrosine phosphatase 1B inhibitor | 0.103 0.076 DBMET00709 | DBMET00709 | |
| 0.003 | 0.872 | 0.072 | Estrogen agonist | 0.072 0.026 DBMET00709 | DBMET00709 | |
| 0.001 | 0.951 | 0.035 | Estrone sulfatase inhibitor | 0.035 0.009 DBMET00709 | DBMET00709 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |